In a report released today, Vamil Divan from Mizuho Securities maintained a Buy rating on Biohaven Pharmaceutical Holding Co (BHVN), with a price target of $85.00. The company’s shares closed last Friday at $67.65.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -1.5% and a 45.5% success rate. Divan covers the Healthcare sector, focusing on stocks such as Satsuma Pharmaceuticals, Karuna Therapeutics, and SAGE Therapeutics.
Currently, the analyst consensus on Biohaven Pharmaceutical Holding Co is a Strong Buy with an average price target of $86.38, which is a 35.6% upside from current levels. In a report issued on July 29, Piper Sandler also maintained a Buy rating on the stock with a $100.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $78.75 and a one-year low of $26.56. Currently, Biohaven Pharmaceutical Holding Co has an average volume of 731.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.